Michael E. Lewis
Präsident bei BioDiligence Partners, Inc.
Profil
Michael E.
Lewis is the founder of Adolor Corp.
(1994), Cephalon, Inc. (1988), Arena Pharmaceuticals, Inc. (1997), and CARA Therapeutics, Inc. (2004).
He is currently a Director at PolyMedix Pharmaceuticals, Inc. (since 2002) and President at BioDiligence Partners, Inc. (since 1994).
He previously held positions as Director at Incara Pharmaceuticals Corp., Vice President-Research at Message Pharmaceuticals, Inc., Senior Director-Scientific Affairs at Cephalon, Inc., Director at Arena Pharmaceuticals, Inc., and Director & Chief Scientific Advisor at CARA Therapeutics, Inc. He also served as an Independent Director at PolyMedix, Inc. (2005-2013) and Aeolus Pharmaceuticals, Inc. (2011-2013).
Dr. Lewis received his undergraduate degree from George Washington University and his graduate and doctorate degrees from Clark University.
Aktive Positionen von Michael E. Lewis
| Unternehmen | Position | Beginn |
|---|---|---|
| PolyMedix Pharmaceuticals, Inc. | Direktor/Vorstandsmitglied | 01.08.2002 |
| BioDiligence Partners, Inc. | Präsident | 01.01.1994 |
Ehemalige bekannte Positionen von Michael E. Lewis
| Unternehmen | Position | Ende |
|---|---|---|
| AEOLUS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 08.05.2013 |
| POLYMEDIX, INC. | Direktor/Vorstandsmitglied | 29.03.2013 |
| Incara Pharmaceuticals Corp. | Direktor/Vorstandsmitglied | 09.08.2004 |
| ARENA PHARMACEUTICALS | Gründer | 01.01.2000 |
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Gründer | - |
Ausbildung von Michael E. Lewis
| Clark University | Doctorate Degree |
| George Washington University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AEOLUS PHARMACEUTICALS, INC. | Health Technology |
| CARA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
| Incara Pharmaceuticals Corp. | Health Technology |
PolyMedix, Inc.
 PolyMedix, Inc. Pharmaceuticals: MajorHealth Technology PolyMedix, Inc. engaged in developing first-in-class, small-molecule defensin-mimetics for the treatment of serious acute care conditions. The company was founded in 2002 and was headquartered in Radnor, PA. | Health Technology |
| PolyMedix Pharmaceuticals, Inc. | |
| BioDiligence Partners, Inc. | |
Message Pharmaceuticals, Inc.
 Message Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Message Pharmaceuticals, Inc. develops pharmaceutical drugs. It operates as research development company involved in RNA research and exploring other types of RNAs to look for RNA-binding proteins, especially to combat RNA viruses and to treat all major disease categories. Message Pharmaceuticals was founded in 2002 and is located in Malvern, PA | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Adolor Corp.
Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Health Technology |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
